Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the impact of two different default dialysate sodium concentrations on major cardiovascular events and death in adults receiving maintenance haemodialysis for end-stage kidney disease. This pragmatic, cluster-randomised, open-label Phase 4 study compares sodium levels of 137 mmoll and 140 mmoll in real-world dialysis settings across multiple sites globally. Dialysis sites will be randomly assigned to use either a default dialysate sodium concentration of 137 mmoll or 140 mmoll for at least 90% of dialysis sessions. Other aspects of patient care will follow standard local practices. Sites must consent to participate, and individual patients will provide waiver or opt-out consent. The study expects to enroll sites over 5 to 7 years, with each participant followed for approximately 2 to 5 years until the study endpoints are reached. Participants will receive dialysis at their assigned sites with the designated sodium concentration. Researchers will monitor the time to first occurrence of major cardiovascular events or death as the primary outcome. Secondary outcomes include other cardiovascular events and individual components of the composite outcomes. Data collection and patient monitoring will continue throughout the study period, estimated to last around five years per participant.
Actively Recruiting
Researchers are evaluating the use of antiplatelet therapy, specifically Aspirin 75 mg daily, to prevent major adverse cardiovascular and cerebrovascular events MACE in patients who have survived intracerebral haemorrhage ICH. This Phase 3, randomized, placebo-controlled, triple-blinded clinical trial plans to recruit 5676 patients aged 18 to 99 years across 50 stroke centers in India. The study aims to address the safety and effectiveness of starting antiplatelet monotherapy after ICH, a question not yet resolved by large trials. Participants will be randomly assigned to receive either daily Aspirin 75 mg or a matching placebo, both alongside standard secondary prevention care. The medication and follow-up duration depend on recruitment timing those recruited in the first year will take the medication for up to three years or until an event occurs, while those recruited later will take it for a minimum of six months with matching follow-up. The total trial duration is three years, with recruitment lasting 2.5 years and follow-up continuing until the study ends. The investigational products are centrally manufactured and dispensed yearly at each site. Participants will undergo face-to-face visits every three months to receive the medication and return unused tablets, with monthly phone calls to monitor adherence and detect any events. Brain imaging by CT or MRI will be done as part of routine care at baseline and if events occur. Researchers will collect clinical data, medication adherence, and functional assessments such as the modified Rankin Scale. Safety monitoring includes event adjudication and follow-up until three years or until withdrawal, death, or event occurrence. The primary outcome is the occurrence of MACE over three years.